JP2023515668A5 - - Google Patents

Info

Publication number
JP2023515668A5
JP2023515668A5 JP2022552546A JP2022552546A JP2023515668A5 JP 2023515668 A5 JP2023515668 A5 JP 2023515668A5 JP 2022552546 A JP2022552546 A JP 2022552546A JP 2022552546 A JP2022552546 A JP 2022552546A JP 2023515668 A5 JP2023515668 A5 JP 2023515668A5
Authority
JP
Japan
Prior art keywords
compound
composition according
pharmaceutically acceptable
acceptable salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022552546A
Other languages
English (en)
Japanese (ja)
Other versions
JP7776430B2 (ja
JP2023515668A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/021037 external-priority patent/WO2021178768A1/en
Publication of JP2023515668A publication Critical patent/JP2023515668A/ja
Publication of JP2023515668A5 publication Critical patent/JP2023515668A5/ja
Priority to JP2025194189A priority Critical patent/JP2026015489A/ja
Application granted granted Critical
Publication of JP7776430B2 publication Critical patent/JP7776430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022552546A 2020-03-06 2021-03-05 Apol-1依存性巣状分節性糸球体硬化症を治療する方法 Active JP7776430B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025194189A JP2026015489A (ja) 2020-03-06 2025-11-13 Apol-1依存性巣状分節性糸球体硬化症を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986096P 2020-03-06 2020-03-06
US62/986,096 2020-03-06
PCT/US2021/021037 WO2021178768A1 (en) 2020-03-06 2021-03-05 Methods of treating apol-1 dependent focal segmental glomerulosclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025194189A Division JP2026015489A (ja) 2020-03-06 2025-11-13 Apol-1依存性巣状分節性糸球体硬化症を治療する方法

Publications (3)

Publication Number Publication Date
JP2023515668A JP2023515668A (ja) 2023-04-13
JP2023515668A5 true JP2023515668A5 (cg-RX-API-DMAC7.html) 2024-03-05
JP7776430B2 JP7776430B2 (ja) 2025-11-26

Family

ID=75223507

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552546A Active JP7776430B2 (ja) 2020-03-06 2021-03-05 Apol-1依存性巣状分節性糸球体硬化症を治療する方法
JP2025194189A Pending JP2026015489A (ja) 2020-03-06 2025-11-13 Apol-1依存性巣状分節性糸球体硬化症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025194189A Pending JP2026015489A (ja) 2020-03-06 2025-11-13 Apol-1依存性巣状分節性糸球体硬化症を治療する方法

Country Status (12)

Country Link
US (2) US11801234B2 (cg-RX-API-DMAC7.html)
EP (1) EP4114385A1 (cg-RX-API-DMAC7.html)
JP (2) JP7776430B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260077861A (cg-RX-API-DMAC7.html)
CN (1) CN115209894B (cg-RX-API-DMAC7.html)
AU (1) AU2021230562B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022017189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3173808A1 (cg-RX-API-DMAC7.html)
IL (1) IL296035A (cg-RX-API-DMAC7.html)
MX (1) MX2022010748A (cg-RX-API-DMAC7.html)
TW (1) TWI865738B (cg-RX-API-DMAC7.html)
WO (1) WO2021178768A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4114385A1 (en) 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017965A2 (en) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines as pesticides
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
WO2002028831A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
ATE510834T1 (de) 2003-03-14 2011-06-15 Astellas Pharma Inc C-glykosid-derivate zur behandlung von diabetes
WO2005092854A1 (en) 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
EA011158B1 (ru) 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
JP2008524162A (ja) 2004-12-16 2008-07-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
JP5175191B2 (ja) 2005-08-30 2013-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
BRPI0615882A2 (pt) 2005-09-08 2011-05-31 Boehringer Ingelheim Int formas cristalinas de 1-cloro-4-(beta-d-glicopiranos-1-il)-2-(4-etinil-benzil)- benzeno, métodos para sua preparação e o uso para preparar medicamentos do mesmo
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AR059489A1 (es) 2006-02-15 2008-04-09 Boehringer Ingelheim Vetmed Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US8283326B2 (en) 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
AR063569A1 (es) 2006-11-06 2009-02-04 Boehringer Ingelheim Int Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion
CL2007003227A1 (es) 2006-11-09 2008-07-04 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo en combinacion con uno o mas agentes terapeuticos; y uso para el tratamiento de diabetes mellitus, obesidad e hiperglucemia entre otras.
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
EP2178870B1 (en) 2007-08-17 2018-09-19 LG Chem, Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
US10130632B2 (en) * 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
CN104007258B (zh) * 2013-09-30 2016-07-06 中国医学科学院基础医学研究所 局灶性节段性肾小球硬化的蛋白标志物
WO2016029310A1 (en) 2014-08-27 2016-03-03 The Governing Council Of The University Of Toronto Cannabinoid type 1 receptor modulators
BR112017007178A2 (pt) 2014-10-08 2017-12-19 Ass Francaise Contre Les Myopathies compostos de aminopiridina úteis como inibidores de prenilação de proteína
HRP20210472T1 (hr) 2015-08-27 2021-05-14 Pfizer Inc. Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4
CN106539843A (zh) * 2017-01-11 2017-03-29 刘国勇 山竹在制备治疗局灶节段性肾小球硬化药物方面的新用途
EP3787669A4 (en) 2018-04-30 2022-03-30 The Trustees of Indiana University COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
LT3897833T (lt) * 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
EP4114385A1 (en) 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
US20230014907A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
KR20240051990A (ko) 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
TWI595873B (zh) 用於治療中樞誘發噁心及嘔吐之組成物及方法
EP3626270B1 (en) Treatment of cardiovascular diseases
ES2259289T3 (es) Formulacion de benzamida con actividad inhibidora de la histona desacetilasa.
JP2013521303A5 (cg-RX-API-DMAC7.html)
KR102319078B1 (ko) 궤양성 대장염의 치료용 의약 조성물
JP2022548687A5 (cg-RX-API-DMAC7.html)
CN105050624A (zh) 利用阿普斯特来治疗银屑病关节炎的方法
US20160158202A1 (en) Low Dose Pharmaceutical Composition
CN1461218A (zh) 阿洛地平和贝那普利的治疗组合
JP2022500485A5 (cg-RX-API-DMAC7.html)
US20090233882A1 (en) Methods and Compositions for the Treatment of Gastrointestinal Disorders
WO2010006103A1 (en) Method for enhancing cognition or inhibiting cognitive decline
TWI674907B (zh) 包括HMG-CoA還原酶抑制劑及鈣通道阻斷劑之組合製劑
CN103249415B (zh) 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
CA1237077A (en) Analgesic combinations
US7625940B2 (en) Method of treating hypertension with a very low dose of chlorthalidone
JP2024505515A5 (cg-RX-API-DMAC7.html)
CN100453081C (zh) 用于治疗糖尿病性肾病的吡啶基亚磺酰氨基嘧啶
JP2022550458A5 (cg-RX-API-DMAC7.html)
KR20060130619A (ko) 유기 화합물의 조합물
CA2823655A1 (en) Methods for treating prostatitis
US11648252B2 (en) Methotrexate for use as a medicament
TW201206433A (en) Association of xanthine oxidase inhibitors and calcium antagonists and use thereof
JP2008044871A (ja) 心血管疾患予防・治療剤
JP2026516115A (ja) 胃食道逆流症(GERD)を治療するためのリナプラザングルレート(linaprazan glurate)